<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1138">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04679272</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0682</org_study_id>
    <nct_id>NCT04679272</nct_id>
  </id_info>
  <brief_title>Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients</brief_title>
  <acronym>ProCOVRA</acronym>
  <official_title>Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients : ProCOVRA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 is an infectious disease caused by SARS-CoV2 virus. The objective of our study is to&#xD;
      analyze the progression and the severity of COVID-19 in patients with RA. Indeed, few data&#xD;
      are available on this subject, and this would allow us to improve management of COVID-19 in&#xD;
      these potential at-risk patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalization rates for COVID-19</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion of hospitalized patients in RA group or control group. From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Critical care transfer rate for COVID-19 and death due to COVID-19</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion of patients transferred in critical care for COVID-19 or deaths due to COVID-19 From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary comorbidities, corticosteroids or DMARDs use</measure>
    <time_frame>1 day</time_frame>
    <description>Type and severity of patients pulmonary comorbidities and treatment by corticosteroids or DMARDs in RA group From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age</measure>
    <time_frame>1 day</time_frame>
    <description>Patients demographics From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with co-morbidities</measure>
    <time_frame>1 day</time_frame>
    <description>Patients comorbidities From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of clinical presentation</measure>
    <time_frame>1 day</time_frame>
    <description>Patients COVID-19 clinical presentation From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of associated treatments</measure>
    <time_frame>1 day</time_frame>
    <description>From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Covid19</condition>
  <condition>Rheumatoid Arthritis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Study population description: *&#xD;
&#xD;
          -  Patients with RA, included in the French RMD Covid-19 cohort, with a confirmed&#xD;
             COVID-19 diagnosis (positive PCR or serology).&#xD;
&#xD;
          -  Patients included in the Montpellier COVID-19 cohort, without autoimmune disease or&#xD;
             inflammatory rheumatism, and with a confirmed COVID-19 diagnosis (positive PCR or&#xD;
             serology).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        - Confirmed COVID-19 diagnosis (positive PCR or serology) in RA patients or healthy&#xD;
        controls.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Age under 18 years old&#xD;
&#xD;
          -  Suspected COVID-19 diagnosis (typical symptoms without a positive PCR or serology)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Padern Guillaume, physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals of Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 20, 2020</study_first_submitted>
  <study_first_submitted_qc>December 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DMARDs</keyword>
  <keyword>Biotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

